Eloralintide is a selective amylin receptor agonist investigated for the treatment of obesity in a 48-week phase 2 clinical trial that was multicenter, double-blind, randomized, and placebo-controlled. The results showed that eloralintide caused a clinically significant reduction in body weight that was dose-dependent. During 48 weeks of treatment, patients taking eloralintide experienced a greater weight loss compared to placebo. The treatment was generally well tolerated, with no serious adverse effects, supporting its potential use in obesity therapy. This study confirms that eloralintide may be an effective and safe treatment option for overweight or obese patients. However, detailed statistics on the exact percentage or kilogram weight loss are not provided in the available text.